Validation of "Clinical Red Flags" for RA-ILD in an Italian cohort
- PMID: 40740947
- PMCID: PMC12307416
- DOI: 10.3389/fmed.2025.1625742
Validation of "Clinical Red Flags" for RA-ILD in an Italian cohort
Abstract
Introduction: Rheumatoid arthritis (RA) is a systemic inflammatory disease, characterized by articular and extra-articular manifestations, including Interstitial Lung Disease (ILD). An early diagnosis of ILD can be essential in improving disease outcome. A clinical practice checklist has previously been proposed, highlighting red flags in signs and symptoms suggestive of RA-ILD. Our aim was to validate the "checklists of red flags signs or symptoms suggestive of RA-ILD" in our cohort of RA patients, by assessing the diagnostic utility of dyspnea, cough, and crackles, both individually and in combination.
Methods: We performed a retrospective study including medical charts of consecutive RA patients fulfilling 2010 ACR/EULAR classification criteria. The diagnosis of RA-ILD was based on the chest HRCT exam. The primary symptoms and signs of ILD, namely cough, crackles, and dyspnea, were considered separately and in combination to determine diagnostic performance metrics.
Results: Our cohort included 107 patients with RA, from which 55 (51.4%) with a diagnosis of RA-ILD. Female patients were predominant in both RA-ILD and No-ILD groups (56.4 and 82.6% respectively), with a significantly higher proportion in the latter (p = 0.0036). Dyspnea alone demonstrated a good diagnostic utility for RA-ILD with a sensitivity of 63.5% and specificity of 60%, PPV of 60% and an NPV of 63.5%, (p = 0.0203). Additionally, crackles exhibited the highest sensitivity among the individual symptoms (66.7%), a specificity of 57.4% and a significant association with RA-ILD (p = 0.0265). The presence of either dyspnea or crackles confirmed their strong association with RA-ILD (p = 0.0066), with the highest level of accuracy (63.5%) and specificity (63.8%). Also, the combination of cough or dyspnea was significantly associated with RA-ILD (p = 0.0111). A strong correlation was observed between RA-ILD and the presence of both crackles and dyspnea (p = 0.0351). When the three symptoms were combined, the sensitivity was 64.3%, the specificity was 53.2%, the PPV was 32.7%, and the NPV was 81%, but did not reach statistical significance (p = 0.1284).
Conclusion: Overall, crackles and dyspnea were the most significant markers of RA-ILD, both individually, and in combination. This study confirms that the red flags previously identified, especially in combination, show an important accuracy and reliability as clinical biomarkers in the early detection of RA-ILD.
Keywords: cough; crackles; dyspnea; interstitial lung disease; rheumatoid arthritis.
Copyright © 2025 Cela, Bonini, Cavalli, Luciano, Kroegler, Ora, Bergamini, Chiocchi, Rogliani, Chimenti and Conigliaro.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.
Similar articles
-
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3. Cochrane Database Syst Rev. 2022. PMID: 35593186 Free PMC article.
-
Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.Clin Orthop Relat Res. 2024 Dec 1;482(12):2193-2208. doi: 10.1097/CORR.0000000000003185. Epub 2024 Jul 23. Clin Orthop Relat Res. 2024. PMID: 39051924
-
Systemic treatments for metastatic cutaneous melanoma.Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2. Cochrane Database Syst Rev. 2018. PMID: 29405038 Free PMC article.
-
Cyclophosphamide for connective tissue disease-associated interstitial lung disease.Cochrane Database Syst Rev. 2018 Jan 3;1(1):CD010908. doi: 10.1002/14651858.CD010908.pub2. Cochrane Database Syst Rev. 2018. PMID: 29297205 Free PMC article.
-
[Volume and health outcomes: evidence from systematic reviews and from evaluation of Italian hospital data].Epidemiol Prev. 2013 Mar-Jun;37(2-3 Suppl 2):1-100. Epidemiol Prev. 2013. PMID: 23851286 Italian.
References
-
- Atzeni F, Siragusano C, Gómez-Puerta JA. Interstitial lung disease and rheumatoid arthritis. Handbk Syst Autoimmune Dis. (2022) 17:21–40. doi: 10.1016/B978-0-323-91083-5.00010-4 - DOI
LinkOut - more resources
Full Text Sources